Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/23/23 | Sanofi (SNY) | Dupixent for Chronic Obstructive Pulmonary Disease (COPD) | Subscribers Only | Subscribers Only | Subscribers Only |
3/22/23 | Biogen (BIIB) | Tofersen for Amyotrophic Lateral Sclerosis (ALS) | Subscribers Only | Subscribers Only | Subscribers Only |
3/22/23 | 89bio (ETNB) | BIO89-100 for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
3/21/23 | Swedish Orphan Biovitrum (SOBI) | SEL-212 for Gout | Subscribers Only | Subscribers Only | Subscribers Only |
3/21/23 | Altimmune (ALT) | Pemvidutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/23/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
03/24/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
03/27/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
03/25/23 - 03/28/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
03/28/23 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |